KRIBIOLISA™ Denosumab (PROLIA™) ELISA
Enzyme Immunoassay for the quantitative determination of Denosumab (PROLIA) in serum, plasma and cell culture supernatant
Receive your quote directly from the manufacturer.
Introduction:
Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle pain in the arms or legs. Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone (bone resorption).
Intended Use:
The KRIBIOLISA™ Denosumab (PROLIA) ELISA is used as an analytical tool for quantitative determination of Denosumab (PROLIA) in serum, plasma and cell culture supernatant.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Denosumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Denosumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Anti-Denosumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Denosumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
